Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1780 for uncontrolled or resistant hypertension
ChiCTR2600129606Phase 3Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HRS-1780 in hypertension (HTN) (7 arms), sponsored by Army Medical Center of PLA. Primary endpoint: Systolic blood pressure (office). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
HRS-1780
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2600129606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129606.